Sanofi’s Principia purchase fails its first test

Just a day after Sanofi bought Kadmon, the French group got a reminder of the risks involved in acquisitions. Rilzabrutinib, one of the oral BTK inhibitors that Sanofi gained through its $3.7bn purchase of Principia, failed a phase 3 study in its lead indication, the skin disorder pemphigus.